Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex32.htm |
| EX-31.2 - EXHIBIT 31.2 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex31-1.htm |
| EX-10.52 - EXHIBIT 10.52 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex10-52.htm |
| EX-10.51 - EXHIBIT 10.51 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex10-51.htm |
| EX-10.50 - EXHIBIT 10.50 - ACURA PHARMACEUTICALS, INC | tm205365d1_ex10-50.htm |
| 10-K - FORM 10-K - ACURA PHARMACEUTICALS, INC | tm205365d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acura Pharmaceuticals, Inc.
Palatine, Illinois
We hereby consent to the incorporation by reference in the Registration Statements on Form S--3 (Nos. 333-210039, 333-146416 and 333-187075) and Form S-8 (Nos. 333-221645, 333-213017, 333-195612, 333-151653, 333-151620, 333-133172, 333-123615, 333-63288, and 33-98396) of Acura Pharmaceuticals, Inc. of our report dated March 30, 2020, relating to the consolidated financial statements which appear in this Form 10-K. Our report contains an explanatory paragraph regarding the Acura Pharmaceuticals, Inc.’s ability to continue as a going concern.
/s/ BDO USA, LLP
Chicago, Illinois
March 30, 2020